Czechia· CZ-0238465
BESREMI
A ropeginterferon alfa-2b product containing ropeginterferon alfa-2b, registered in Czechia by AOP Orphan Pharmaceuticals GmbH, Wien. The same ATC class is registered in 12 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Ropeginterferon alfa-2b is registered in 12 of 19 countries.
Countries holding a registration under ATC L03AB15 (ropeginterferon alfa-2b), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Ropeginterferon alfa-2b · ATC L03AB15
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- ROPEGINTERFERON ALFA-2B
- Manufacturer
- AOP Orphan Pharmaceuticals GmbH, Wien
- Country
- Czechia (CZ)
- ATC code
- L03AB15
- ATC class
- Ropeginterferon alfa-2b
- Defined daily dose
- 18 mcg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ropeginterferon alfa-2b in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumBesremi 250 µg/0.5 mlAOP Orphan Pharmaceuticals
- SwitzerlandBesremi
- SpainBESREMI 250 MICROGRAMOS/0,5 ML DE SOLUCION PARA INYECCION EN PLUMA PRECARGADAAop Orphan Pharmaceuticals Gmbh
- PolandBesremiAOP Orphan Pharmaceuticals GmbH
- SwedenBesremi 250 mikrogram/0,5 ml Injektionsvätska, lösning i förfylld injektionspennaAop Orphan Pharmaceuticals GmbH
- United StatesBESREMiPharmaEssentia USA
- FinlandBesremiOrifarm Oy
- NorwayBesremiOrifarm AS
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Besremi
- Liechtenstein · Besremi
- Norway · Besremi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c15397ee-35c5-4a0b-9d13-5b4cbe68b95c GET /v1/drugs/c15397ee-35c5-4a0b-9d13-5b4cbe68b95c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL PEP",
"source": "sukl",
"strength": "250MCG/0,5ML",
"pack_size": "1X0,5ML+2J",
"substance": "ROPEGINTERFERON ALFA-2B",
"cz_kod_sukl": "0238465",
"product_type": "BT",
"substance_codes": "20225",
"registration_state": "R",
"registration_number": "EU/1/18/1352/001"
}See everything about ropeginterferon alfa-2b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.